- Home
- Publications
- Publication Search
- Publication Details
Title
Combination immunotherapy: a road map
Authors
Keywords
Immunotherapy, Combination, Checkpoint inhibitors, Preclinical models, Clinical trial, Endpoints
Journal
Journal for ImmunoTherapy of Cancer
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-02-10
DOI
10.1186/s40425-017-0218-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Cancer immunotherapy trials: leading a paradigm shift in drug development
- (2016) Leisha A. Emens et al. Journal for ImmunoTherapy of Cancer
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Advancing Clinical Trials to Streamline Drug Development
- (2015) S. E. Bates et al. CLINICAL CANCER RESEARCH
- Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
- (2015) Deborah A. Knight et al. JOURNAL OF CLINICAL INVESTIGATION
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- The importance of animal models in tumor immunity and immunotherapy
- (2014) Sadna Budhu et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
- (2014) Zhiqiang Guo et al. PLoS One
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
- (2014) S. Iwama et al. Science Translational Medicine
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy
- (2014) Jieqing Chen et al. Journal for ImmunoTherapy of Cancer
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
- (2013) I. Melero et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
- (2013) Michel DuPage et al. CURRENT OPINION IN IMMUNOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
- (2013) S. R. Goding et al. JOURNAL OF IMMUNOLOGY
- Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
- (2013) Silvia C. Formenti et al. JNCI-Journal of the National Cancer Institute
- Tissues in Different Anatomical Sites Can Sculpt and Vary the Tumor Microenvironment to Affect Responses to Therapy
- (2013) Christel Devaud et al. MOLECULAR THERAPY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin
- (2013) Huafeng Wei et al. PLoS One
- Current advances in humanized mouse models
- (2012) Ryoji Ito et al. Cellular & Molecular Immunology
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
- (2012) Hirokazu Matsushita et al. NATURE
- Expression of tumour-specific antigens underlies cancer immunoediting
- (2012) Michel DuPage et al. NATURE
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression
- (2011) Michel DuPage et al. CANCER CELL
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
- (2011) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
- (2011) Michael A. Curran et al. PLoS One
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth
- (2010) M. W. L. Teng et al. CANCER RESEARCH
- Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma
- (2010) Jo Eyles et al. JOURNAL OF CLINICAL INVESTIGATION
- Naive tumor-specific CD4+T cells differentiated in vivo eradicate established melanoma
- (2010) Ying Xie et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
- (2009) M. Z. Dewan et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now